Cytori Therapeutics develops cellular therapeutics for specific diseases and medical conditions. The Company primarily provides Cytori Cell Therapy for the treatment of impaired hand function in scleroderma. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets, and StemSource cell and tissue banking systems, as well as surgical accessories and instruments. The Company also provides a number of products for use in treating various cancers.

Type
Public
HQ
San Diego, US
Founded
2002
Size (employees)
80 (est)
Website
cytori.com
Cytori Therapeutics was founded in 2002 and is headquartered in San Diego, US
Report incorrect company information

Cytori Therapeutics Office Locations

Cytori Therapeutics has offices in Deeside, San Antonio, San Diego and Tokyo
San Diego, US (HQ)
3020 Callan Road
San Antonio, US
12500 Network Blvd
Tokyo, JP
Otemachi Park Building 7F 1-1-1 Otemachi, Chiyoda-ku
Deeside, GB
Deeside Industrial Park East Unit 68, Third Avenue
Show all (4)
Report incorrect company information

Cytori Therapeutics Financials and Metrics

Cytori Therapeutics Financials

Cytori Therapeutics's revenue was reported to be $4.66 m in FY, 2016 which is a 3.8% decrease from the previous period.
USD

Net income (FY, 2017)

(22.7 m)

EBIT (FY, 2017)

(20.7 m)

Market capitalization (23-Apr-2018)

9.3 m

Cash (31-Dec-2017)

9.6 m
Cytori Therapeutics's current market capitalization is $9.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

7.1 m5 m4.8 m4.7 m

Revenue growth, %

(30%)(2%)(4%)

Cost of goods sold

3.4 m2.9 m3.2 m2.7 m

Gross profit

3.7 m2 m1.7 m1.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

15.5 m14.6 m14.3 m12.6 m9.6 m

Accounts Receivable

Inventories

3.7 m3.2 m

Current Assets

24.6 m21.7 m21.2 m18.7 m14.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(26.2 m)(37.4 m)(18.7 m)(22 m)(22.7 m)

Depreciation and Amortization

1.6 m779 k1.1 m1.2 m2.2 m

Inventories

(459 k)(815 k)490 k471 k251 k

Accounts Payable

(409 k)(1.1 m)1 m(673 k)(1.8 m)
USDY, 2017

Financial Leverage

2.4 x
Show all financial metrics
Report incorrect company information